Literature DB >> 14595708

Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood.

Benjamin Gesundheit1, Giannoula Klement, Christof Senger, Robert Kerbel, Mark Kieran, Sylvain Baruchel, Laurence Becker.   

Abstract

BACKGROUND: The clinical manifestations of childhood pilocytic astrocytoma (PA) and anaplastic astrocytoma (AA) markedly differ, especially in the time to progression and prognosis. Because of the aggressive course and poor survival rate of AA, one would expect it to be associated with a high angiogenic index. Counterintuitively, we often find higher microvessel density counts in PA than in AA. PROCEDURE: We examined the differences in type or density of microvasculature between the two neoplasms. To differentiate established, mature vessels from immature growing ones, we used antibodies to Factor VIII (FVIII) to stain endothelial cells (ECs) of blood vessels and alpha-smooth muscle actin (alpha-SMA) antibodies to stain vessels supported by adventitia.
RESULTS: We found that large, mature, alpha-SMA-positive vessels predominated in PA, and small, immature, alpha-SMA-negative vessels in AA. The vessel maturation index was 54.5% for PA, and 6.1% for AA. Immunostaining with vascular endothelial growth factor (VEGF) and anti-flt-1/VEGF receptor-1 antibodies showed distinct tissue patterns. VEGF immunoreactivity occurred mainly in the processes of the tumor astrocytes in PA; the opposite was observed in AA. flt-1/VEGFR-1 was detected in the tumor cells of AA but not in those of PA.
CONCLUSIONS: We propose that the predominance of small, alpha-SMA-negative vessels in AA represents immature, unstable vasculature with a potentially greater susceptibility to anti-angiogenic therapy. The expression of both flt-1 and VEGF by AA tumor cells also suggests a possible autocrine growth-promoting function for VEGF in addition to its role as paracrine pro-angiogenic growth factor for activated ECs, thus making anti-angiogenesis an attractive therapeutic target in the treatment of AA. Copyright 2003 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14595708     DOI: 10.1002/mpo.10308

Source DB:  PubMed          Journal:  Med Pediatr Oncol        ISSN: 0098-1532


  7 in total

1.  Isolation and culture of microvascular endothelial cells from gliomas of different WHO grades.

Authors:  Sabine Miebach; Stefan Grau; Vera Hummel; Peter Rieckmann; Joerg-Christian Tonn; Roland Helmut Goldbrunner
Journal:  J Neurooncol       Date:  2006-01       Impact factor: 4.130

2.  Angiogenic patterns and their quantitation in high grade astrocytic tumors.

Authors:  Suash Sharma; Mehar C Sharma; Deepak Kumar Gupta; Chitra Sarkar
Journal:  J Neurooncol       Date:  2006-06-29       Impact factor: 4.130

3.  Co-existent pilocytic astrocytoma with acute B-cell leukemia within the cerebellum.

Authors:  Richard Hickman; Rebecca Leeman-Neill; Marc Rosenblum; Richard Anderson; James Goldman
Journal:  Neuropathology       Date:  2019-08-13       Impact factor: 1.906

4.  Efficacy of bevacizumab plus irinotecan in children with recurrent low-grade gliomas--a Pediatric Brain Tumor Consortium study.

Authors:  Sridharan Gururangan; Jason Fangusaro; Tina Young Poussaint; Roger E McLendon; Arzu Onar-Thomas; Shengjie Wu; Roger J Packer; Anu Banerjee; Richard J Gilbertson; Frederic Fahey; Sridhar Vajapeyam; Regina Jakacki; Amar Gajjar; Stewart Goldman; Ian F Pollack; Henry S Friedman; James M Boyett; Maryam Fouladi; Larry E Kun
Journal:  Neuro Oncol       Date:  2013-12-04       Impact factor: 12.300

Review 5.  The treatment of high grade gliomas and diffuse intrinsic pontine tumors of childhood and adolescence: a historical - and futuristic - perspective.

Authors:  Jonathan L Finlay; Stergios Zacharoulis
Journal:  J Neurooncol       Date:  2005-12       Impact factor: 4.130

6.  Phase II TPDCV protocol for pediatric low-grade hypothalamic/chiasmatic gliomas: 15-year update.

Authors:  Kavita K Mishra; Sarah Squire; Kathleen Lamborn; Anuradha Banerjee; Nalin Gupta; William M Wara; Michael D Prados; Mitchel S Berger; Daphne A Haas-Kogan
Journal:  J Neurooncol       Date:  2010-03-11       Impact factor: 4.130

7.  CRAdRGDflt-IL24 virotherapy in combination with chemotherapy of experimental glioma.

Authors:  L N Kaliberova; V Krendelchtchikova; D K Harmon; C R Stockard; A S Petersen; J M Markert; G Y Gillespie; W E Grizzle; D J Buchsbaum; S A Kaliberov
Journal:  Cancer Gene Ther       Date:  2009-04-10       Impact factor: 5.987

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.